

AARDVARK BIOTECH LIMITED
ABBREVIATED ACCOUNTS FOR THE YEAR ENDED
31ST JANUARY 2010



Company Registration Number 03502208

AARDVARK BIOTECH LIMITED**ABBREVIATED BALANCE SHEET 31st JANUARY 2010**

	<u>2010</u>	<u>2009</u>
TANGIBLE FIXED ASSETS (Note 2)	1	1
CURRENT ASSETS		
Cash at Bank and in hand	154	154
CREDITORS: Amounts falling due within one year	—	—
NET CURRENT ASSETS	<u>154</u>	<u>154</u>
TOTAL ASSETS	£ 155	£ 155
	<u> </u>	<u> </u>
CAPITAL AND RESERVES		
Called-up equity share capital (Note 3)	100	100
Profit and Loss Account	<u>55</u>	<u>55</u>
SHAREHOLDERS FUNDS	£ 155	£ 155
	<u> </u>	<u> </u>

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the accounts for the year by virtue of section 480 and that no member or members have requested an audit pursuant to section 476 of the Act

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions for companies subject to the small companies regime.

These financial statements were approved by the directors on the 26th February 2010 and are signed on their behalf by

S Davey

Dr S N DAVEY

AARDVARK BIOTECH LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS
YEAR ENDED 31ST JANUARY 2010

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost Convention, and in accordance with the provisions for companies subject to the small companies regime

2 TANGIBLE FIXED ASSETS

COST

At 1st February 2009 and 31st January 2010

Equipment

£ 1659

DEPRECIATION

At 1st February 2009 and
31st January 2010

£ 1658

NET BOOK VALUE

At 31st January 2010 (At 31st January 2009 £1)

£ 1

3 SHARE CAPITAL

Authorised share capital:

100 Ordinary shares of £1 each

100

100

Allotted, called up and fully paid

Ordinary share capital

100

100

4 RELATED PARTY TRANSACTIONS

The company was under the control of Dr S N Davey throughout the current year and previous period Dr S N Davey is the managing director and majority shareholder.